본문 바로가기
KERD
논문KCI 등재

Versatile roles of innate lymphoid cells at the mucosal barrier: from homeostasis to pathological inflammation

Kim Jinwoo|김혜영|Ryu Seungwon|Lim MinYeong
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2023.12|Experimental and Molecular Medicine|제55권 |pp. 1845-1857|DOI 10.1038/s12276-023-01022-z

2

조회

0

다운로드

1

인용

0

참고문헌

주제분류생화학

초록

Innate lymphoid cells (ILCs) are innate lymphocytes that do not express antigen-specific receptors and largely reside and self-renew in mucosal tissues. ILCs can be categorized into three groups (ILC1–3) based on the transcription factors that direct their functions and the cytokines they produce. Their signature transcription factors and cytokines closely mirror those of their Th1, Th2, and Th17 cell counterparts. Accumulating studies show that ILCs are involved in not only the pathogenesis of mucosal tissue diseases, especially respiratory diseases, and colitis, but also the resolution of such diseases. Here, we discuss recent advances regarding our understanding of the biology of ILCs in mucosal tissue health and disease. In addition, we describe the current research on the immune checkpoints by which other cells regulate ILC activities: for example, checkpoint molecules are potential new targets for therapies that aim to control ILCs in mucosal diseases. In addition, we review approved and clinically- trialed drugs and drugs in clinical trials that can target ILCs and therefore have therapeutic potential in ILC-mediated diseases. Finally, since ILCs also play important roles in mucosal tissue homeostasis, we explore the hitherto sparse research on cell therapy with regulatory ILCs. This review highlights various therapeutic approaches that could be used to treat ILC-mediated mucosal diseases and areas of research that could benefit from further investigation.

Abstract

Innate lymphoid cells (ILCs) are innate lymphocytes that do not express antigen-specific receptors and largely reside and self-renew in mucosal tissues. ILCs can be categorized into three groups (ILC1–3) based on the transcription factors that direct their functions and the cytokines they produce. Their signature transcription factors and cytokines closely mirror those of their Th1, Th2, and Th17 cell counterparts. Accumulating studies show that ILCs are involved in not only the pathogenesis of mucosal tissue diseases, especially respiratory diseases, and colitis, but also the resolution of such diseases. Here, we discuss recent advances regarding our understanding of the biology of ILCs in mucosal tissue health and disease. In addition, we describe the current research on the immune checkpoints by which other cells regulate ILC activities: for example, checkpoint molecules are potential new targets for therapies that aim to control ILCs in mucosal diseases. In addition, we review approved and clinically- trialed drugs and drugs in clinical trials that can target ILCs and therefore have therapeutic potential in ILC-mediated diseases. Finally, since ILCs also play important roles in mucosal tissue homeostasis, we explore the hitherto sparse research on cell therapy with regulatory ILCs. This review highlights various therapeutic approaches that could be used to treat ILC-mediated mucosal diseases and areas of research that could benefit from further investigation.

참고문헌 (177)

  1. Vivier, E., "Innate lymphoid cells : 10 years on", Cell, 174, pp.1054~1066 (2018)
  2. 김지현, "Innate Lymphoid Cells in Tissue Homeostasis and Disease Pathogenesis", Molecules and Cells, 44(5), pp.301~309 (2021), 한국분자세포생물학회[DOI]
  3. Zhang, J., "T-bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1", Eur. J. Immunol, 48, pp.738~750 (2018)
  4. Wagner, J. A., "Stage-specific requirement for eomes in mature NK cell homeostasis and cytotoxicity", Cell Rep, 31, pp.107720~ (2020)
  5. Chiossone, L., "Natural killer cells and other innate lymphoid cells in cancer", Nat. Rev. Immunol, 18, pp.671~688 (2018)
  6. Entwistle, L. J., "Pulmonary group 2 innate lymphoid cell phenotype is context specific : determining the effect of strain, location, and stimuli", Front. Immunol, 10, pp.3314~ (2020)
  7. Monticelli, L. A., "Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus", Nat. Immunol, 12, pp.1045~1054 (2011)
  8. Turner, J-E., "IL-9–mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation", J. Exp. Med, 210, pp.2951~2965 (2013)
  9. Gschwend, J., "Alveolar macrophages rely on GM-CSF from alveolar epithelial type 2 cells before and after birth", J. Exp. Med, 218, pp.e20210745~ (2021)
  10. Meininger, I., "Tissue-specific features of innate lymphoid cells", Trends Immunol, 41, pp.902~917 (2020)
  11. Schroeder, J-H., "Transcription factor-driven regulation of ILC1 and ILC3", Trends Immunol, 43, pp.564~579 (2022)
  12. Montaldo, E., "Group 3 innate lymphoid cells(ILC3s) : origin, differentiation, and plasticity in humans and mice", Eur. J. Immunol, 45, pp.2171~2182 (2015)
  13. Kim, M., "Colonization and effector functions of innate lymphoid cells in mucosal tissues", Microbes Infect, 18, pp.604~614 (2016)
  14. Gasteiger, G., "Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs", Science, 350, pp.981~985 (2015)
  15. Zhong, C., "Differential expression of the transcription factor GATA3 specifies lineage and functions of innate lymphoid cells", Immunity, 52, pp.83~95 (2020)
  16. Ghaedi, M., "Single-cell analysis of RORalpha tracer mouse lung reveals ILC progenitors and effector ILC2 subsets", J. Exp. Med, 217 (2020)[DOI]
  17. Orimo, K., "Characteristics of tissue-resident ILCs and their potential as therapeutic targets in mucosal and skin inflammatory diseases", Allergy, 76, pp.3332~3348 (2021)
  18. Zeis, P., "In situ maturation and tissue adaptation of type 2 innate lymphoid cell progenitors", Immunity, 53, pp.775~792 (2020)
  19. Possot, C., "Notch signaling is necessary for adult, but not fetal, development of RORgammat(+)innate lymphoid cells", Nat. Immunol, 12, pp.949~958 (2011)
  20. Constantinides, M. G., "A committed precursor to innate lymphoid cells", Nature, 508, pp.397~401 (2014)
  21. Erle, D. J., "Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes", J. Immunol, 153, pp.517~528 (1994)
  22. Deem, T. L., "Vascular cell adhesion molecule 1 (VCAM-1)activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species", Blood, 104, pp.2385~2393 (2004)
  23. Chea, S., "CXCR6 expression is important for retention and circulation of ILC precursors", Mediators Inflamm, 2015, pp.368427~ (2015)
  24. Kim, M. H, "Retinoic acid differentially regulates the migration of innate lymphoid cell subsets to the gut", Immunity, 43, pp.107~119 (2015)
  25. Patman, G., "Immunology : gut migration of innate lymphoid cells", Nat. Rev. Gastroenterol. Hepatol, 12, pp.430~430 (2015)
  26. Stier, M. T., "IL-33 promotes the egress of group 2 innate lymphoid cells from the bone marrow", J. Exp. Med, 215, pp.263~281 (2018)
  27. Corral, D., "ILC precursors differentiate into metabolically distinct ILC1-like cells during Mycobacterium tuberculosis infection", Cell Rep, 39, pp.110715~ (2022)
  28. Fuchs, A., "Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15-responsive IFN-gamma-producing cells", Immunity, 38, pp.769~781 (2013)
  29. Luci, C., "Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin", Nat. Immunol, 10, pp.75~82 (2009)
  30. Klose, C. S., "A T-bet gradient controls the fate and function of CCR6-RORγt+innate lymphoid cells", Nature, 494, pp.261~265 (2013)
  31. Hewitt, R. J., "Regulation of immune responses by the airway epithelial cell landscape", Nat. Rev. Immunol, 21, pp.347~362 (2021)
  32. Mjosberg, J., "Human innate lymphoid cells", J. Allergy Clin. Immunol, 138, pp.1265~1276 (2016)
  33. Stephen T., "Asthma", Nat. Rev. Dis. Primers, 1 (2015)[DOI]
  34. Ham, J., "Memory-like innate lymphoid cells in the pathogenesis of asthma", Front. Immunol, 13 (2022)[DOI]
  35. 함종호, "Targeting the Epithelium-Derived Innate Cytokines: From Bench to Bedside", Immune Network, 22(1), pp.1~26 (2022), 대한면역학회[DOI]
  36. Halim, T. Y., "Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation", Immunity, 40, pp.425~435 (2014)
  37. Grotenboer, N. S., "Decoding asthma : translating genetic variation in IL33 and IL1RL1 into disease pathophysiology", J. Allergy Clin. Immunol, 131, pp.856~865 (2013)
  38. Tamari, M., "Genome-wide association studies of allergic diseases", Allergol. Int, 62, pp.21~28 (2013)
  39. Liu, T., "Type 2 innate lymphoid cells : a novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma", Respir. Med, 109, pp.1391~1396 (2015)
  40. Bartemes, K. R., "Enhanced innate type 2immune response in peripheral blood from patients with asthma", J. Allergy. Clin. Immunol, 134, pp.671~678 (2014)
  41. Kim, J., "Innate immune crosstalk in asthmatic airways: Innate lymphoid cells coordinate polarization of lung macrophages", J. Allergy Clin. Immunol, 143, pp.1769~1782 (2019)
  42. Akar-Ghibril, N., "Allergic endotypes and phenotypes of asthma", J. Allergy Clin. Immunol. Pract, 8, pp.429~440 (2020)
  43. Kim, H. Y., "Interleukin-17-producing innate lymphoid cells and the NLRP3inflammasome facilitate obesity-associated airway hyperreactivity", Nat. Med, 20, pp.54~61 (2014)
  44. Estrella, B., "Effects of air pollution on lung innate lymphoid cells: review of in vitro and in vivo experimental studies", Int. J. Environ. Res. Public Health, 16 (2019)[DOI]
  45. Kim, J., "The effect of air pollutants on airway innate immune cells in patients with asthma", Allergy, 75, pp.2372~2376 (2020)
  46. Luo, J., "Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells", J. Allergy Clin. Immunol, 144, pp.1722~1726 (2019)
  47. Ploeg, E. K. V. D., "Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseases", Sci. Immunol, 6, pp.eabd3489~ (2021)
  48. Liu, S., "Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin", J. Allergy Clin. Immunol, 141, pp.257~268 (2018)
  49. Moriyama, S., "β2-adrenergic receptor-mediated negative regulation of group 2 innate lymphoid cell responses", Science, 359, pp.1056~1061 (2018)
  50. Rabe, K. F., "Chronic obstructive pulmonary disease", Lancet, 389, pp.1931~1940 (2017)
  51. Blomme, E. E., "Quantification and role of innate lymphoid cell subsets in Chronic Obstructive Pulmonary Disease", Clin. Transl. Immunology, 10, pp.e1287~ (2021)
  52. Freeman, C. M., "Cytotoxic potential of lung CD8(+)T cells increases with chronic obstructive pulmonary disease severity and with in vitro stimulation by IL-18 or IL-15", J. Immunol, 184, pp.6504~6513 (2010)
  53. Wang, Z., "Interferon γ Induction of Pulmonary Emphysema in the Adult Murine Lung", J. Exp. Med, 192, pp.1587~1600 (2000)
  54. Freeman, C. M., "Human CD56+ cytotoxic lung lymphocytes kill autologous lung cells in chronic obstructive pulmonary disease", PLoS One, 9, pp.e103840~ (2014)
  55. Finch, D. K., "Lung dendritic cells drive natural killer cytotoxicity in chronic obstructive pulmonary disease via IL-15 Ralpha", Am. J. Respir. Crit. Care Med, 198, pp.1140~1150 (2018)
  56. Silver, J. S., "Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs", Nat. Immunol, 17, pp.626~635 (2016)
  57. Bal, S. M., "IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs", Nat. Immunol, 17, pp.636~645 (2016)
  58. Kearley, J., "Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection", Immunity, 42, pp.566~579 (2015)
  59. De Grove, K. C., "Characterization and quantification of innate lymphoid cell subsets in human lung", PLoS One, 11, pp.e0145961~ (2016)
  60. Suzuki, M., "The cellular and molecular determinants of emphysematous destruction in COPD", Sci. Rep, 7, pp.9562~ (2017)
  61. Torres, A., "Pneumonia", Nat. Rev. Dis. Primers, 7, pp.25~ (2021)
  62. Stehle, C., "Innate lymphoid cells in lung infection and immunity", Immunol. Rev, 286, pp.102~119 (2018)
  63. Dou, Y., "Influenza vaccine induces intracellular immune memory of human NK cells", PLoS One, 10, pp.e0121258~ (2015)
  64. Wills-Karp, M., "Innate lymphoid cells wield a double-edged sword", Nat. Immunol, 12, pp.1025~1027 (2011)
  65. Gorski, S. A., "Group 2 innate lymphoid cell production of IL-5 is regulated by NKT cells during influenza virus infection", PLoS Pathog, 9, pp.e1003615~ (2013)
  66. Gomes, A. M. C., "SARS-CoV2 pneumonia recovery is linked to expansion of innate lymphoid cells type 2 expressing CCR10", Eur. J. Immunol, 51, pp.3194~3201 (2021)
  67. Silverstein, N. J., "Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection", Elife, 11, pp.e74681~ (2022)
  68. Van Maele, L., "Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection", J. Infect. Dis, 210, pp.493~503 (2014)
  69. Mowat, A. M., "Regional specialization within the intestinal immune system", Nat. Rev. Immunol, 14, pp.667~685 (2014)
  70. Yudanin, N. A., "Spatial and temporal mapping of human innate lymphoid cells reveals elements of tissue specificity", Immunity, 50, pp.505~519 (2019)
  71. Diefenbach, A., "Innate lymphoid cell-epithelial cell modules sustain intestinal homeostasis", Immunity, 52, pp.452~463 (2020)
  72. Sonnenberg, G. F., "Border patrol : regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22", Nat. Immunol, 12, pp.383~390 (2011)
  73. Sawa, S., "RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota", Nat. Immunol, 12, pp.320~326 (2011)
  74. Zheng, Y., "Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens", Nat. Med, 14, pp.282~289 (2008)
  75. Sugimoto, K., "IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis", J. Clin. Invest, 118, pp.534~544 (2008)
  76. Satoh-Takayama, N., "Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense", Immunity, 29, pp.958~970 (2008)
  77. Sonnenberg, G. F., "CD4(+)lymphoid tissue-inducer cells promote innate immunity in the gut", Immunity, 34, pp.122~134 (2011)
  78. Lindemans, C. A., "Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration", Nature, 528, pp.560~564 (2015)
  79. Jarade, A., "Inflammation triggers ILC3 patrolling of the intestinal barrier", Nat. Immunol, 23, pp.1317~1323 (2022)
  80. Chun, E., "Metabolite-sensing receptor Ffar2 regulates colonic Group 3innate lymphoid cells and gut", Immunity, 51, pp.871~884 (2019)
  81. Kinnebrew, M. A., "Interleukin 23 production by intestinal CD103(+)CD11b(+)dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense", Immunity, 36, pp.276~287 (2012)
  82. Longman, R. S., "CX(3)CR1(+)mononuclear phagocytes support colitisassociated innate lymphoid cell production of IL-22", J. Exp. Med, 211, pp.1571~1583 (2014)
  83. Takatori, H., "Lymphoid tissue inducer-like cells are an innate source of IL-17and IL-22", J. Exp. Med, 206, pp.35~41 (2009)
  84. Powell, N., "The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells", Immunity, 37, pp.674~684 (2012)
  85. Bhatt, B., "Gpr109a limits microbiota-induced IL-23 production to constrain ILC3-mediated colonic inflammation", J. Immunol, 200, pp.2905~2914 (2018)
  86. Cella, M., "Expansion of human NK-22 cells with IL-7, IL-2, and IL-1β reveals intrinsic functional plasticity", Proc. Natl. Acad. Sci. USA, 107, pp.10961~10966 (2010)
  87. Zeng, B., "ILC3 function as a double-edged sword in inflammatory bowel diseases", Cell Death Dis, 10, pp.315~ (2019)
  88. Song, C., "Unique and redundant functions of NKp46 + ILC3s in models of intestinal inflammation", J. Exp. Med, 212, pp.1869~1882 (2015)
  89. Chang, Y., "Increased GM-CSF-producing NCR(-)ILC3s and neutrophils in the intestinal mucosa exacerbate inflammatory bowel disease", Clin. Transl. Immunol, 10, pp.e1311~ (2021)
  90. Eken, A., "IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism", Mucosal Immunol, 7, pp.143~154 (2014)
  91. Castellanos, J. G., "Microbiota-Induced TNF-like ligand 1 A drives group 3innate lymphoid cell-mediated barrier protection and intestinal T cell activation during colitis", Immunity, 49, pp.1077~1089 (2018)
  92. Bouchery, T., "ILC2s-trailblazers in the host response against intestinal helminths", Front. Immunol, 10, pp.623~ (2019)
  93. Neill, D. R., "Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity", Nature, 464, pp.1367~1370 (2010)
  94. Price, A. E., "Systemically dispersed innate IL-13-expressing cells in type 2immunity", Proc. Natl. Acad. Sci. USA, 107, pp.11489~11494 (2010)
  95. Ricardo-Gonzalez, R. R., "Tissue signals imprint ILC2 identity with anticipatory function", Nat. Immunol, 19, pp.1093~1099 (2018)
  96. Huang, Y., "S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense", Science, 359, pp.114~119 (2018)
  97. Wang, S., "Regulatory innate lymphoid cells control innate intestinal inflammation", Cell, 171, pp.201~216 (2017)
  98. Hutloff, A., "ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28", Nature, 397, pp.263~266 (1999)
  99. Coyle, A. J., "The CD28-related molecule ICOS is required for effective T celldependent immune responses", Immunity, 13, pp.95~105 (2000)
  100. Toker, A., "Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma", Clin. Cancer Res, 24, pp.5685~5696 (2018)
  101. Dong, C., "ICOS co-stimulatory receptor is essential for T-cell activation and function", Nature, 409, pp.97~101 (2001)
  102. Van, D. V., "ICOS costimulation differentially affects T cells in secondary lymphoid organs and inflamed tissues", Am. J. Respir. Cell Mol. Biol, 59, pp.437~447 (2018)
  103. Paclik, D., "ICOS regulates the pool of group 2 innate lymphoid cells under homeostatic and inflammatory conditions in mice", Eur. J. Immunol, 45, pp.2766~2772 (2015)
  104. Maazi, H., "ICOS : ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity", Immunity, 42, pp.538~551 (2015)
  105. Kamachi, F., "ICOS promotes group 2innate lymphoid cell activation in lungs", Biochem. Biophys. Res. Commun, 463, pp.739~745 (2015)
  106. Iwanaga, N., "Host immunology and rational immunotherapy for carbapenem-resistant Klebsiella pneumoniae infection", JCI Insight, 5, pp.e135591~ (2020)
  107. Ward-Kavanagh, L. K., "The TNF receptor superfamily in co-stimulating and co-inhibitory responses", Immunity, 44, pp.1005~1019 (2016)
  108. Tian, J., "The role of GITR", GITRL interaction in autoimmune diseases, 2020, pp.11, 588682~
  109. Galle-Treger, L., "Costimulation of type-2 innate lymphoid cells by GITR promotes effector function and ameliorates type 2 diabetes", Nat. Commun, 10, pp.713~ (2019)
  110. Nagashima, H., "GITR cosignal in ILC2s controls allergic lung inflammation", J. Allergy Clin. Immunol, 141, pp.1939~1943 (2018)
  111. Vashist, N., "Influenza-activated ILC1s contribute to antiviral immunity partially influenced by differential GITR expression", Front. Immunol, 9, pp.505~ (2018)
  112. Cavagnero, K. J., "Unconventional ST2- and CD127-negative lung ILC2populations are induced by the fungal allergen Alternaria alternata", J. Allergy Clin. Immunol, 144, pp.1432~1435 (2019)
  113. Sugamura, K., "Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40", Nat. Rev. Immunol, 4, pp.420~431 (2004)
  114. Halim, T. Y. F., "Tissue-restricted adaptive type 2 immunity is orchestrated by expression of the costimulatory molecule OX40L on group 2 innate lymphoid cells", Immunity, 48, pp.1195~1207 (2018)
  115. Wu, J., "Critical role of OX40", OX40L in ILC2-mediated activation of CD4(+)T cells during respiratory syncytial virus infection in mice, 2019, pp.76, 105784~
  116. Drake, L. Y., "Group 2 innate lymphoid cells and CD4 + T cells cooperate to mediate type 2 immune response in mice", Allergy, 69, pp.1300~1307 (2014)
  117. Deng, T., "ILC3-derived OX40L is essential for homeostasis of intestinal Tregs in immunodeficient mice", Cell Mol. Immunol, 17, pp.163~177 (2020)
  118. McLaren, J. E., "The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro", J. Immunol, 184, pp.5827~5834 (2010)
  119. Twohig, J. P., "The death receptor 3", TL1A pathway is essential for efficient development of antiviral CD4(+)and CD8(+)T-cell immunity, 2012, pp.26, 3575~3586
  120. Valatas, V., "TL1A(TNFSF15)and DR3(TNFRSF25) : a costimulatory system of cytokines with diverse functions in gut mucosal immunity", Front. Immunol, 10, pp.583~ (2019)
  121. Prehn, J. L., "The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells", J. Immunol, 178, pp.4033~4038 (2007)
  122. Ahn, Y. O., "Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation", Eur. J. Immunol, 45, pp.2335~2342 (2015)
  123. Meylan, F., "The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells", Mucosal Immunol, 7, pp.958~968 (2014)
  124. Yu, X., "TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers", Mucosal Immunol, 7, pp.730~740 (2014)
  125. Machida, K., "Type 2 innate lymphoid cells expressing death receptor 3 are increased in airway of mild atopic asthmatic subject following allergen inhalation challenge", J. Allergy Clin. Immunol, 141 (2018)[DOI]
  126. Li, J., "Activation of DR3 signaling causes loss of ILC3s and exacerbates intestinal inflammation", Nat. Commun, 10, pp.3371~ (2019)
  127. Ishida, Y., "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death", EMBO J, 11, pp.3887~3895 (1992)
  128. Andrews, L. P., "Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups", Nat. Immunol, 20, pp.1425~1434 (2019)
  129. Day, C. L., "PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression", Nature, 443, pp.350~354 (2006)
  130. Pardoll, D. M., "The blockade of immune checkpoints in cancer immunotherapy", Nat. Rev. Cancer, 12, pp.252~264 (2012)
  131. Yu, Y., "Single-cell RNA-seq identifies a PD-1(hi)ILC progenitor and defines its development pathway", Nature, 539, pp.102~106 (2016)
  132. Taylor, S., "PD-1 regulates KLRG1(+)group 2 innate lymphoid cells", J. Exp. Med, 214, pp.1663~1678 (2017)
  133. Seillet, C., "Deciphering the innate lymphoid cell transcriptional program", Cell Rep, 17, pp.436~447 (2016)
  134. Vacca, P., "PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua", Mucosal Immunol, 12, pp.624~631 (2019)
  135. Tumino, N., "Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors : Functional analysis and expression of PD-1receptor", Int. J. Cancer, 145, pp.1660~1668 (2019)
  136. Mariotti, F. R., "Innate lymphoid cells : expression of PD-1 and other checkpoints in normal and pathological conditions", Front. Immunol, 10, pp.910~ (2019)
  137. Mallett, G., "Programmed cell death-1 receptor(PD-1)-mediated regulation of innate lymphoid cells", Int. J. Mol. Sci, 20, pp.2836~ (2019)
  138. Helou, D. G., "PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity", Nat. Commun, 11, pp.3998~ (2020)
  139. Myklebust, J. H., "High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells", Blood, 121, pp.1367~1376 (2013)
  140. Huntington, N. D., "NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation", J. Immunol, 178, pp.4764~4770 (2007)
  141. Huang, Y., "IL-25-responsive, lineage-negative KLRG1(hi)cells are multipotential ‘inflammatory’ type 2 innate lymphoid cells", Nat. Immunol, 16, pp.161~169 (2015)
  142. Mazzurana, L., "Tissue-specific transcriptional imprinting and heterogeneity in human innate lymphoid cells revealed by full-length single-cell RNAsequencing", Cell Res, 31, pp.554~568 (2021)
  143. Blanquart, E., "Targeting androgen signaling in ILC2s protects from IL-33-driven lung inflammation, independently of KLRG1", J. Allergy Clin. Immunol, 149, pp.237~251 (2022)
  144. Nagasawa, M., "KLRG1 and NKp46 discriminate subpopulations of human CD117(+)CRTH2(-)ILCs biased toward ILC2 or ILC3", J. Exp. Med, 216, pp.1762~1776 (2019)
  145. Golebski, K., "Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response", Immunity, 54, pp.291~307 (2021)
  146. Cobb, L. M., "Therapeutic manipulation of innate lymphoid cells", JCI Insight, 6, pp.e146006~ (2021)
  147. Matsuyama, T., "The therapeutic potential for targeting group 2 innate lymphoid cells in asthma", Front. Immunol, 13, pp.930862~ (2022)
  148. Kelsen, S. G., "Astegolimab(anti-ST2)efficacy and safety in adults with severe asthma : a randomized clinical trial", J Allergy Clin. Immunol, 148, pp.790~798 (2021)
  149. Yousuf, A. J., "Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease(COPD-ST2OP) : a phase 2a, placebo-controlled trial", Lancet Respir. Med, 10, pp.469~477 (2022)
  150. Wechsler, M. E., "Efficacy and safety of itepekimab in patients with moderate-to-severe asthma", N. Engl. J. Med, 385, pp.1656~1668 (2021)
  151. O’Byrne, P. M., "Development of an inhaled anti-TSLP therapy for asthma", Pulm. Pharmacol. Ther, 78, pp.102184~ (2022)
  152. Sands, B. E., "Ustekinumab as induction and maintenance therapy for ulcerative colitis", N. Engl. J. Med, 381, pp.1201~1214 (2019)
  153. Reich, K., "A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis", N. Engl. J. Med, 365, pp.1586~1596 (2011)
  154. Reich, K., "Guselkumab versus secukinumab for the treatment of moderateto-severe psoriasis(ECLIPSE) : results from a phase 3, randomised controlled trial", Lancet, 394, pp.831~839 (2019)
  155. Gordon, K. B., "Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis(UltIMMa-1 and UltIMMa-2) : results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials", Lancet, 392, pp.650~661 (2018)
  156. Imai, Y., "Dupilumab effects on innate lymphoid cell and helper T cell populations in patients with atopic dermatitis", JID Innov, 1, pp.100003~ (2021)
  157. Ortega, H. G., "Mepolizumab treatment in patients with severe eosinophilic asthma", N. Engl. J. Med, 371, pp.1198~1207 (2014)
  158. Castro, M., "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts : results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials", Lancet Respir. Med, 3, pp.355~366 (2015)
  159. Langley, R. G., "Secukinumab in plaque psoriasis–results of two phase 3trials", N. Engl. J. Med, 371, pp.326~338 (2014)
  160. Gordon, K. B., "Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis", N. Engl. J. Med, 375, pp.345~356 (2016)
  161. Keisuke Orimo, "Innate Lymphoid Cells in the Airways: Their Functions and Regulators", Allergy, Asthma & Immunology Research, 12(3), pp.381~398 (2020), 대한천식알레르기학회
  162. Xue, L., "Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells", J. Allergy Clin. Immunol, 133, pp.1184~1194 (2014)
  163. Farne, H., "Effect of CRTH2 antagonism on the response to experimental rhinovirus infection in asthma : a pilot randomised controlled trial", Thorax, 77, pp.950~959 (2021)
  164. Brightling, C. E., "Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma(LUSTER-1 and LUSTER-2) : two phase 3 randomised controlled trials", Lancet Respir. Med, 9, pp.43~56 (2021)
  165. Leff, J. A., "Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction", N. Engl. J. Med, 339, pp.147~152 (1998)
  166. Salimi, M., "Cysteinyl leukotriene E(4) activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D(2) and epithelial cytokines", J. Allergy Clin. Immunol, 140, pp.1090~1100 (2017)
  167. Moriyama, S., "beta(2)-adrenergic receptor-mediated negative regulation of group 2 innate lymphoid cell responses", Science, 359, pp.1056~1061 (2018)
  168. Feagan, B. G., "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N. Engl. J. Med, 369, pp.699~710 (2013)
  169. Dai, B., "Dual targeting of lymphocyte homing and retention through alpha4beta7 and alphaEbeta7 inhibition in inflammatory bowel disease", Cell Rep. Med, 2, pp.100381~ (2021)
  170. Peyrin-Biroulet, L., "Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors(HICKORY) : a phase 3, randomised, controlled trial", Lancet Gastroenterol. Hepatol, 7, pp.128~140 (2022)
  171. Forkel, M., "Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established crohn’s disease and ulcerative colitis", J. Crohns Colitis, 13, pp.67~78 (2019)
  172. Georas, S. N., "JAK inhibitors for asthma", J. Allergy Clin. Immunol, 148, pp.953~963 (2021)
  173. Stabile, H., "JAK", STAT signaling in regulation of innate lymphoid cells : the gods before the guardians, 2018, pp.286, 148~159
  174. Robinette, M. L., "Jak3 deficiency blocks innate lymphoid cell development", Mucosal Immunol, 11, pp.50~60 (2018)
  175. Sandborn, W. J., "Tofacitinib as induction and maintenance therapy for ulcerative colitis", N. Engl. J. Med, 376, pp.1723~1736 (2017)
  176. Simpson, E. L., "Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids : results from two randomized monotherapy phase III trials", Br. J. Dermatol, 183, pp.242~255 (2020)
  177. Guttman-Yassky, E., "Upadacitinib in adults with moderate to severe atopic dermatitis : 16-week results from a randomized, placebo-controlled trial", J. Allergy Clin. Immunol, 145, pp.877~884 (2020)

관련 논문AI추천

Unconventional immune cells in the gut mucosal barrier: regulation by symbiotic microbiotaOh Sungwhan F., Yoo Ji-Sun생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Deciphering the complexities of mucosal innate lymphocytes: guardians and potential therapeutic targets김지형, 김혜영생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Regulation of Intestinal Homeostasis by Innate Immune CellsHisako Kayama, Junichi Nishimura, Kiyoshi Takeda대한면역학회 · Immune Network2013 · 제13권 제6호The modulation of pulmonary group 2 innate lymphoid cell function in asthma: from inflammatory mediators to environmental and metabolic factorsChang Ya-Jen, Thio Christina Li-Ping생화학분자생물학회 · Experimental and Molecular Medicine2023 · 제55권 Heterogeneity of IL-22-producing Lymphoid Tissue Inducer-like Cells in Human and Mouse김미연, 김수찬, 한신석대한면역학회 · Immune Network2010 · 제10권 제4호Tissue-Specific Metabolic Reprogramming in Innate Lymphoid Cells and Its Impact on Disease김혜영, 양우석, 함종호대한면역학회 · Immune Network2025 · 제25권 제1호

이 간행물의 다른 논문 (225건)

Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics김성영, Han Yeaeunpp. 1-12Grave-to-cradle: human embryonic lineage tracing from the postmortem bodyKu Eu Jeong, Choi Seock Hwan, Choi Yujin Angelina, Oh Ji Wonpp. 13-21Chromatin and noncoding RNA-mediated mechanisms of gastric tumorigenesisKim Tae-Hee, Loe Adrian Kwan Ho, Zhu Lexinpp. 22-31TPX2 prompts mitotic survival via the induction of BCL2L1 through YAP1 protein stabilization in human embryonic stem cellsCha Hyuk-Jin, Kim Yun-Jeong, Go Young-Hyun, 정호창, Kwon Eun-Ji, Kim Seong-Min, Cheong Hyun Sub, Kim Wantae, Shin Hyoung Doo, Lee Haeseungpp. 32-42ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5Nam Hae Yun, 김성학, 김승후, 최경철, Park Seung-Ho, Song Ji-Hye, Jeong Ji-Hoon, Kim Hyunhee, Jeong Minseok, Kong Min-Jeong, Son Jihyun, Jeong Ji-Eunpp. 43-54
원문 보기